Ralaniten triacetate

SKU: orb1693793

Description

Ralaniten triacetate (EPI-506) is an orally bioavailable, first-in-class inhibitor targeting the androgen receptor N-terminal domain. It demonstrates anticancer activity and is a valuable research tool for investigating prostate and breast cancer in both in vitro and in vivo experimental models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1637573-04-6
• MW: 521.00
• Purity: 99.37% (May vary between batches)
• Formula: C₂₇H₃₃ClO₈
• SMILES: CC(=O)OC[C@H](COc1ccc(cc1)C(C)(C)c1ccc(OC[C@@H](CCl)OC(C)=O)cc1)OC(C)=O
• Target: Androgen Receptor
• Solubility: 10% DMSO+90% Corn Oil:3.3 mg/mL (6.33 mM);DMSO:80 mg/mL (153.55 mM)

Bioactivity

• In Vitro:
  Ralaniten triacetate (EPI-506) is a highly specific small molecule targeting the N-terminal domain (NTD) of the androgen receptor (AR). It is commonly used in research on metastatic castration-resistant prostate cancer (mCRPC), where resistance to androgen deprivation therapy has developed.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AndrogenReceptor, Androgen Receptor, EPI-506, Ralaniten

Compound Identifiers

PubChem CID

86278934